Jacobs Levy Equity Management
SPRY icon

Jacobs Levy Equity Management’s ARS Pharmaceuticals SPRY Stock Holding History

Jacobs Levy Equity Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-101,397
Closed -$1.07M – 1193
2024
Q4 		$1.07M Sell
101,397
-551,651
-84% -$7.73M ﹤0.01% 705
2024
Q3 		$9.47M Buy
653,048
+288,021
+79% +$3.43M 0.04% 331
2024
Q2 		$3.11M Buy
365,027
+87,321
+31% +$775K 0.01% 526
2024
Q1 		$2.84M Buy
277,706
+257,589
+1,280% +$1.92M 0.01% 534
2023
Q4 		$110K Buy
+20,117
New +$88.1K ﹤0.01% 951
2023
Q3 		– Sell
-37,903
Closed -$254K – 1058
2023
Q2 		$254K Sell
37,903
-257,368
-87% -$1.72M ﹤0.01% 905
2023
Q1 		$1.92M Sell
295,271
-3,345
-1% -$25.7K 0.01% 581
2022
Q4 		$2.55M Sell
298,616
-152,218
-34% -$988K 0.02% 508
2022
Q3 		$2.38M Buy
+450,834
New +$2.22M 0.02% 528

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jacobs Levy Equity Management's SPRY Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 101,397 shares — an estimated $1.07M sold.

Jacobs Levy Equity Management first reported a position in SPRY in Q3 2022 and held it in 9 quarters. The position peaked at $9.47M in Q3 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Jacobs Levy Equity Management reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 101,397 ARS Pharmaceuticals shares in Q1 2025, an estimated $1.07M.
  • Jacobs Levy Equity Management first reported a position in ARS Pharmaceuticals in Q3 2022 and held it in 9 quarters.
  • Jacobs Levy Equity Management's ARS Pharmaceuticals position peaked at $9.47M in Q3 2024.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.